A study showing new drug, Donanemab could slow Alzheimer’s disease progression by 35% in patients in the earliest stages of the disease has been supported by NIF nodes at the University of Melbourne and Macquarie University.
Supporting NIF Partners
A study showing new drug, Donanemab could slow Alzheimer’s disease progression by 35% in patients in the earliest stages of the disease has been supported by NIF nodes at the University of Melbourne and Macquarie University.